Ability Pharma, a CataloniaBio & HealthTech member, has closed a €2.3-million round of funding to complete Phase II clinical trials on its drug for endometrial and lung cancer (ABTL0812). Later, the objective is to reach a licensing agreement with a pharmaceutical company to continue development and commercialisation of the drug.
Participants in theinvestment round included the new venture capital fund Inveready Biotech III managed by Inveready and the FiTalent corporate venture fund of Everis Group. Last December, Ability raised €1.2 million euros through a crowdfunding round with Capital Cell.
“We’ve seen promising results in the ongoing clinical trials in Spain and France. If the results are confirmed with all patients, ABTL0812 will revolutionise the treatment of endometrial cancer,” says Dr Carles Domènech, executive president and scientific director of Ability.
In order to strengthen the executive team, Maribel Berges has joined the company as CEO. Berges has more than 20 years of experience in the pharmaceutical and biomedical industry. Previously, she was in charge of financial and business managementat Spherium Biomed, a company recently acquired by Ferrer. Overthe same period, Maribel Berges was vice-president of CataloniaBioHT.
“Ability has demonstrated a unique ability to achieve excellent results, with remarkable financial efficiency, through partial licenses and non-dilutive financing instruments. At this key moment, we are reinforcing the team to achieve the intended objectives,” says Roger Piqué, general partner of Inveready.
Photo: Maribel Berges, new CEO of Ability, ata CataloniaBioHT event
Comments